Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

C. Son



Author of

  • +

    P2.10 - Poster Session 2 - Chemotherapy (ID 207)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P2.10-018 - Drug selection in non-small cell lung cancer patients: perspective of Korean physician (ID 1210)

      09:30 - 09:30  |  Author(s): C. Son

      • Abstract

      Background
      The main purpose of chemotherapy in patients of non-small cell lung cancer (NSCLC) is similar in both physician and patients, prolonging survival time and improve quality of life. But, priority of the criteria for selection of regimen is different. To investigate types of systemic anticancer therapy in patients with NSCLC, to describe regimen-wise characteristics of patients’ clinical profile, and to examine factors influencing the selection of regimen.

      Methods
      This observational study was conducted at 19 study centers in Korea from June 2008 to July 2010. Patients above 18 years of age with histologically confirmed NSCLC stage IIIa, IIIb, or IV, who received systemic chemotherapy for lung cancer for the first time and were willing to provide written consent, were included in the study. Descriptive statistics were performed on the data collected.

      Results
      In total, 435 patients were included and evaluated in the study. Docetaxel (85.1%) was the most common drug prescribed followed by carboplatin (46.4%) and cisplatin (37.9%). Across regimens, no difference in the distribution of patients for tumor-node-metastasis stage, histology of the disease as well as previous chemotherapy and radiation therapy was observed. Of all the reasons for selecting chemotherapy, efficacy as measured by disease free survival/overall survival was reported as being “most important” in the highest proportion (28.1%, 122/435) of patients.

      Conclusion
      For the physicians, the first priority of regimen selecting chemotherapy was efficacy, different from patients’ perspective, adverse effects. We should evaluate this again in the era of new drugs with less side effects.

  • +

    P2.13 - Poster Session 2 - SCLC (ID 201)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P2.13-003 - Prognostic factors for extensive stage small cell lung cancer. (ID 1846)

      09:30 - 09:30  |  Author(s): C. Son

      • Abstract

      Background
      Despite a high cheomosensitivity, the long term survival of extensive stage small cell lung cancer is poor. But the individual prognosis is variable. We want to evaluate prognostic factors in extensive small cell lung cancer..

      Methods
      We retrospectively analyzed clinical and laboratory characteristics of 129 patients who were diagnosed extensive stage small cell lung cancer. Clinical and laboratory characteristics were analyzed.

      Results
      The median survival time is 196 days (95% confidence interval[CI], 162 to 229 days). Univariate analysis showed that gender, body mass index(BMI), performance status(PS), the presence of superior vena cava(SVC) syndrome, diabetes, and anemia were associated survival.(all P-value≤0.031). Multivariate Cox regression analysis indicate that survival time was independently associates with BMI(<18.5) (hazard ratio [HR];6.56, 95% CI 2.83–15.21; p = 0.000), the presence of SVC syndrome([HR];3.54, 95% CI 1.50–8.36; p = 0.004) and the presence of anemia ([HR];1.83, 95% CI 1.01–3.34; p = 0.047).

      Conclusion
      In this study, lower BMI, the presence of SVC syndrome and the presence of anemia were poor prognostic factor for survival.